ebook_ADHD2019_spanish

8. Kuczenski R, Segal DS. Differential effects of D- and L-amphetamine and methylphenidate on rat striatal dopamine biosynthesis. Eur J Pharmacol. 1975;30(2):244-51. 9. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 1996;379(6566):606-12. 10. van der Voet M, Harich B, Franke B, Schenck A. ADHD-associated dopamine transporter, latrophi- lin and neurofibromin share a dopamine-related locomotor signature in Drosophila. Mol Psychiatry. 2016;21(4):565-73. 11. van der Kooij MA, Glennon JC.Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder. Neurosci Biobehav Rev. 2007;31(4):597-618. 12. Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U. Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. Am J Psychiatry. 2012;169(3):264-72. 13. Bralten J, Franke B, Waldman I, Rommelse N, Hartman C, Asherson P, et al. Candidate genetic pathways for attention-deficit/hyperactivity disorder (ADHD) show association to hyperactive/impulsive symptoms in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2013;52(11):1204-1212.e1. 14. Arnsten AF, Pliszka SR. Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacol Biochem Behav. 2011;99(2):211-6. 15. de la Peña JB, Dela Peña IJ, Custodio RJ, Botanas CJ, Kim HJ, Cheong JH. Exploring the validity of proposed transgenic animal models of attention-deficit hyperactivity disorder (ADHD). Mol Neurobiol. 2018;55(5):3739-3754. 16. Vanicek T, Spies M, Rami-Mark C, Savli M, Höflich A, Kranz GS, et al. The norepinephrine transporter in attention-deficit/hyperactivity disorder investigated with positron emission tomography. JAMA Psychia- try. 2014;71(12):1340-1349. 17. Klein M, Onnink M, van Donkelaar M, Wolfers T, Harich B, Shi Y, et al. Brain imaging genetics in ADHD and beyond – mapping pathways from gene to disorder at different levels of complexity. Neurosci Biobehav Rev. 2017;80:115-155. 18. Banerjee E, Nandagopal K. Does serotonin deficit mediate susceptibility to ADHD? Neurochem Int. 2015;82:52-68. 19. Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet. 2009;126(1):51-90. 20. van der Meer D, Hartman CA, Richards J, Bralten JB, Franke B, Oosterlaan J, et al. The serotonin transporter gene polymorphism 5-HTTLPR moderates the effects of stress on attention-deficit/hyperactivity disorder. J Child Psychol Psychiatry. 2014;55(12):1363-71. 21. Zhou Y, Danbolt NC. Glutamate as a neurotransmitter in the healthy brain. J Neural Transm (Vienna). 2014;121(8):799-817. 22. Gregory KJ, Noetzel MJ, Niswender CM. Pharmacology of metabotropic glutamate receptor allos- teric modulators: structural basis and therapeutic potential for CNS disorders. Prog Mol Biol Transl Sci. 2013;115:61-121. 23. Elia J, Glessner JT, Wang K, Takahashi N, Shtir CJ, Hadley D, et al. Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disor- der. Nat Genet. 2011;44(1):78-84. 24. Naaijen J, Bralten J, Poelmans G, IMAGE consortium, Glennon JC, Franke B, et al. Glutamatergic and GABAergic gene sets in attention-deficit/hyperactivity disorder: association to overlapping traits in ADHD and autism. Transl Psychiatry. 2017;7(1):e999. 40 Rohde, Buitelaar, Gerlach & Faraone (editores)